Plecanatide 3 mg once daily effective for managing severe constipation in adults with CIC or IBS-C
An article published in Neurogastroenterology and Motility entitled "Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation" by Dr Brooks D. Cash et al. and colleagues have concluded that plecanatide remains an option for managing patients with chronic idiopathic constipation or CIC and irritable bowel syndrome with constipation or IBS-C, including those with severe baseline symptoms.
This study found that 3- and 6-mg doses of plecanatide are superior to placebo for patients with severe CIC and IBS-C.
Patients with CIC and IBS-C experience severe symptoms. In this study, the team aimed to evaluate plecanatide in adults with CIC or IBS-C with symptoms of severe constipation.
Data were analyzed post hoc from trials CIC, IBS-C of plecanatide 3 mg, 6 mg, or placebo for 12 weeks. They measured primary efficacy endpoints as durable overall CSBM responders (CIC: ≥3 CSBMs/week, plus increase from baseline of ≥1 CSBM/week, for ≥9 of 12 weeks, including ≥3 of the last four weeks) and overall responders (IBS-C: ≥30% reduction from baseline in abdominal pain and ≥1 CSBM/week increase for ≥6 of 12 weeks.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.